Drug Trial Radar · NCT01337089
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Last checked: Nov 20, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
660
Actual
Start
Jan 19, 2011
Primary completion
Jan 27, 2016
Study completion Jan 27, 2016
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- First posted
- Apr 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3 study and new (de novo) participants.
Conditions
- Pain
- Advanced Cancer
Interventions
NabiximolsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Of Participants With Treatment-emergent Adverse EventsTime frame: Baseline, Day 183
Locations
128 sites in 18 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
El Cajon, California
Site not named
Gilroy, California
Site not named
Glendale, California
Site not named
Santa Rosa, California
Site not named
Clearwater, Florida
Site not named
Daytona Beach, Florida
Site not named
Holiday, Florida
Site not named
Jacksonville, Florida
Site not named
Lynn Haven, Florida
Site not named
Miami, Florida
Site not named
Stuart, Florida
Site not named
Tampa, Florida
Site not named
Winter Park, Florida
Site not named
Marietta, Georgia
Site not named
Newnan, Georgia
Site not named
Stockbridge, Georgia
Site not named
Woodlawn, Illinois
Site not named
Ashland, Kentucky
Site not named
Bossier City, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Saint Louis Park, Minnesota
Site not named
Kansas City, Missouri
Site not named
Missoula, Montana
Site not named
Berlin, New Jersey
Site not named
New York, New York
Site not named
New York, New York
Site not named
Flat Rock, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cleveland, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Houston, Texas
Site not named
Laredo, Texas
Site not named
Salt Lake City, Utah
Site not named
Salt Lake City, Utah
Site not named
Lacey, Washington
Site not named
Parkville, Australia
Site not named
Brussels, Belgium
Site not named
Gabrovo, Bulgaria
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.